Diabetes is a condition involving high blood glucose, or sugar. Weight can play a key role in the disease, as it can lead to both weight loss and weight gain.

Statistics show that 34.2 million people in the United States have diabetes. This represents 10.5% of the population. Type 2 diabetes can cause weight loss if a person does not receive treatment.

On the other hand, weight gain may also occur once a person starts insulin therapy. In fact, virtually every person who takes the therapy experiences this side effect. But there are other medications for type 2 diabetes that can cause weight loss or no change in weight.

After a person develops type 2 diabetes, following a balanced diet is important for controlling blood sugar levels and helping prevent weight gain, which, according to this 2011 study, worsens the progression of the disease. This involves eating balanced meals of nutritious foods and watching portion sizes.

Keep reading to learn more about type 2 diabetes and weight loss, as well as diet tips and recommendations.

Insulin is a hormone that allows sugar to exit the bloodstream and enter the cells that use it for energy. In type 2 diabetes, the cells do not respond to insulin as they should. This is called insulin resistance.

As a consequence, the pancreas produces more insulin to overcome the resistance. Eventually, the pancreas is unable to make enough insulin to get a sufficient amount of sugar into the cells. This causes blood sugar levels to rise.

Since the cells cannot get the energy they need from glucose, the body breaks down fat to use for energy instead. This can result in weight loss.

Weight loss without obvious causes may be a symptom of type 2 diabetes. Obvious causes of weight loss include intentionally dieting, exercising regularly, or taking diuretics, which are medications that increase urination.

When medication and other therapies for type 2 diabetes fail to control blood sugar, doctors typically recommend insulin therapy. This happens in about 25% of people with the condition, and most people who begin insulin therapy gain weight.

There is also evidence that weight gain is less pronounced in people who already have obesity. When a person needs insulin therapy, the benefit of controlling blood sugars far outweighs the risk of weight gain. A person can take steps to help limit weight gain by following moderate diet recommendations such as those discussed below.

Insulin resistance, which is a hallmark of type 2 diabetes, may also lead to weight gain. When the pancreas produces more insulin in response to insulin resistance, the hormone signals the muscles and liver to store blood sugar. After the muscles and liver are full, the liver sends excess blood sugar to fat cells for storage. This can also lead to weight gain.

Some oral medications, such as glipizide and pioglitazone, can cause weight gain as well. Other medications, such as metformin, liraglutide, and dapagliflozin, may cause weight loss in some people and have no effect on weight in others. It is important for each person to talk with their doctor about what treatment options might be best in their circumstances.

Learn more about medications for diabetes here.

Nutrition is a vital part of a balanced lifestyle for a person with type 2 diabetes, notes the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). It helps keep blood sugar levels in the target range, as well as promoting weight loss or weight maintenance. These benefits increase energy and help delay the development of diabetes complications.

The optimum diet for people with diabetes involves eating nutritious foods from all food groups in the correct quantity. The Centers for Disease Control and Prevention (CDC) advocate for The Plate Method as a meal-planning guide. The Plate Method involves:

A person may drink water or unsweetened iced tea with their meal.

Learn more about the best vegetables for type 2 diabetes here.

The NIDDK advises limiting the following:

In addition, if a person consumes alcohol, females should limit intake to one drink per day, and males should limit intake to two drinks per day.

Other CDC dietary recommendations include:

Planning meals that meet a persons health needs and budget may pose a challenge, so consulting with a registered dietitian can be helpful. Another option involves asking a doctor for a referral to a diabetes self-management and education service. This program teaches people how to eat healthily, check their blood sugar, and emotionally cope with diabetes.

Learn about dinner ideas for type 2 diabetes here.

Other symptoms of type 2 diabetes include:

The symptoms often develop slowly over several years. Many people do not have symptoms, and some experience symptoms that are too mild to notice. Sometimes individuals do not discover they have diabetes until they develop one of the complications, such as heart disease.

Learn more about the early symptoms of diabetes here.

In type 1 diabetes, the pancreas either does not make insulin, or it makes very little, notes the CDC. This causes blood sugar to rise because insufficient insulin is available to allow it to enter the cells.

As in type 2 diabetes, because the body cannot get enough of the glucose it needs for energy, it breaks down body fat to use as energy. This can cause weight loss.

Type 2 diabetes can cause weight loss. Some treatments for type 2 diabetes can also cause weight gain or loss.

If a person has type 2 diabetes, diet plays a critical role in blood sugar control. In addition, when someone has overweight, the loss of even a few pounds can help them manage their condition. With this in mind, an individuals eating plan is very important because it affects blood sugar and weight, both of which determine the progression of diabetes.

People with diabetes may wish to consider consulting a registered dietitian to get personalized recommendations and help in following a balanced eating plan.

See the original post:
Type 2 diabetes and weight loss: Diet, recommendations, and more - Medical News Today

While the trends have indicated for months now that lifestyle diseases like hypertension and diabetes have made the second wave of COVID-19 pandemic in India extremely dangerous, a recent Lancet study corroborated those trends as facts.

According to an article in The Print a Lancet report states that the findings from a large-scale COVID-19 study conducted in India revealed that patients from Madurai had an increased risk of death compared to those in China, Europe, South Korea, and the United States even though 63 percent of those tested were asymptomatic. According to the report, chronic health problems such as diabetes and hypertension played a crucial role in amplifying the effects of COVID-19 and causing fatalities.

The Print said that the study found that, The death rate was 5.7% among Covid-19 patients with at least one existing health condition, compared to 0.7% in those who were otherwise healthy, the researchers found. The data came from more than 400,000 people who underwent coronavirus testing known as RT-PCR in Madurai from May 20 to October 31, 2020, during Indias first wave."The report further stated that due to extreme underreport, it is hard to access the true impact of COVID-19 due to the massive underreporting of fatalities.

The article claimed that after accessing the ratio between infections and fatalities, the researchers also pointed out the extreme underreporting of COVID-related deaths.

For some time now, patterns emerging from Covid management across the country indicate that people with co-morbidities of non-communicable diseases (NCDs) have a higher mortality rate than those who do not.

In an interview with IANS, Dr. Ambrish Mittal, Chairman and Head, Endocrinology and Diabetes Department, Max Healthcare (Pan Max), had previously said, Diabetes has risen exponentially in India from 2 per cent in the 1970s in urban areas to between 10-20 per cent in 2020. The cases of diabetes are even higher in metros at 35-40 per cent. This spike is linked to urbanization led by economic development and has been more prevalent in urban areas as compared to rural areas."

(With inputs from IANS)

Read all the Latest News, Breaking News and Coronavirus News here

Here is the original post:
Lifestyle Diseases Like Diabetes And Hypertension Made The 2nd Wave of India's COVID Pandemic Deadly, Says - News18

MALVERN, Pa. and NEW YORK, Aug. 17, 2021 /PRNewswire/ --LifeScan, a world leader in blood glucose monitoring, serving more than 20 million people with diabetes and the maker of the iconic OneTouch brand products, and Cecelia Health, one of the nation's most scalable virtual care companies focused on diabetes and chronic disease management, today announced the addition of a fully integrated live telehealth service with the OneTouch Reveal app.

Building on the success of their 2020 partnership, LifeScan and Cecelia Health will launch a new live Certified Diabetes Care and Education Specialists (CDCES) telehealth service through the highly rated OneTouch Reveal app.

"Cecelia Health has been an incredibly important partner to LifeScan by bringing their unmatched Certified Diabetes Care and Education Specialist capabilities through our OneTouch Reveal app to care for, educate, and empower people with diabetes," said Val Asbury, LifeScan president and chief executive officer. "We are proud to expand upon our partnership with Cecelia Health's live telehealth service, together adding the connectivity, convenience and the personalized support that we know helps improve health outcomes and overall well-being."

"Our expanded partnership with Cecelia Health has an important role in the larger digital ecosystem of connected solutions and services LifeScan is creating to help support a healthy lifestyle for the millions of people with diabetes who count on OneTouch brand products every day," Asbury said.

This expanded partnership with Cecelia Health is another way that LifeScan continues to focus on the individual needs of people with diabetes and other chronic conditions, and their caregivers, to promote effective management. Cecelia Health's CDCES support model has a proven track record of increasing medication adherence by 23% and reducing A1C values by an average of 1.5 points. Cecelia Health's support model coupled with LifeScan's OneTouch Reveal app, which uses a cloud-based patient-engagement ecosystem linking people to providers, offers a powerful combination of data, technology, and human insight to optimize diabetes and other chronic disease management.

"We're thrilled to expand our partnership with LifeScan to provide people living with diabetes the best care possible. Adding a live telehealth service enables the development of deep and lasting relationships with people who use OneTouch products, educating and guiding them on their journey to better health outcomes," said Mark Clermont, Cecelia Health CEO. "This partnership is emblematic of LifeScan's vision to create a world without limits for people with diabetes and related conditions, and I am proud that Cecelia Health's clinical teams have a role in supporting this goal."

With this partnership, people with diabetes and related health conditions who count on OneTouch products will develop one-on-one personal relationships with their Cecelia Certified Diabetes Care and Education Specialist (CDCES). Certified care specialists will help them better manage their blood sugar levels and overall health by providing support on diet and exercise, mental wellness, and technical aspects of diabetes device management. Personalized support will be initiated through the OneTouch Reveal app, creating a seamless experience and eliminating fatigue from usage of multiple communication platforms.

The Certified Diabetes Care and Education Specialist (CDCES) live telehealth support will be available on the OneTouch Reveal app and will be fully integrated into OneTouch Solutions, a new portal designed to offer a choice of support, guidance and digital tools to help people with diabetes thrive in their own way. OneTouch Solutions will be offered to consumers in the US starting this Fall, and then offered to healthcare providers and payors as a reimbursed adjudicated option in early 2022.

About the OneTouch brand made by LifeScanLifeScan is a global leader in blood glucose monitoring innovation and digital health technology and has a vision to create a world without limits for people with diabetes and related conditions. More than 20 million people and their caregivers around the world count on LifeScan's OneTouch brand products to manage their diabetes. Together, LifeScan and OneTouch improve the quality of life for people with diabetes with products and digital platforms defined by simplicity, accuracy, and trust. http://www.LifeScan.com and http://www.OneTouch.com

About Cecelia HealthCecelia Health is a virtual-first provider organization delivering integrated care to patients across all chronic disease risk profiles. We address critical care gaps, reduce variability in care, and improve medication and device adherence. Our mission is to positively transform the lives of individuals living with chronic conditions.

Our virtual specialty care solution delivers the optimal mix of clinical interventions with digital touchpoints. We offer a comprehensive suite of synchronous and asynchronous disease management capabilities including remote clinical coaching, device training, remote patient monitoring, and telemedicine delivered via a national network of specialty providers. To date, Cecelia Health has delivered virtual care to over 200,000 people with chronic illness.

SOURCE Lifescan, Inc.; Cecelia Health

http://www.lifescan.com

Read more:
LifeScan and Cecelia Health Sign Expanded Multi-Year Partnership to Offer Live Diabetes Telehealth Support in Combination with OneTouch Solutions...

CASES of diabetes are on the rise in young people, driven by the obesity crisis.

Being aware of the signs could prevent serious complications from the disease if a child or young person gets an early diagnosis.

1

Diabetes is a serious condition which needs lifelong management.

Unfortunately, type 2 diabetes - which accounts for 90 per cent of all cases - is accelerating as a result of factors including obesity.

More often than not, the condition is triggered by poor lifestyle habits like eating too much unhealthy food or not exercising.

The effects are now being seen in children, some younger than 12 years old, who previously were more likely to get type 1 diabetes, which is genetic.

New figures show a 60 per cent increase in under 25s with type 2 diabetes being treated at paediatric diabetes units in England and Wales over five years.

There were 866 under-25s who got treatment in 2019/20 compared with the 322 in 2014/15, according to the stats published by Royal College of Paediatrics and Child Health.

Just over 84 per cent of the patients were registered as obese, broadly in line with previous years.

Nikki Joule, policy manager at Diabetes UK, said: Type 2 diabetes is no longer just a condition found in older people; it can affect any age.

We also know that type 2 diabetes is likely to have more severe and acute consequences, if they develop it as children especially if they do not have access to the right specialist treatment and support.

Childhood obesity is the main driver behind the rise in cases."

It comes after a new report revealed almost 1,600 children under 19 in England have type 2 diabetes.

Diabetes UK warned that the NHS Digital data on August 12 confirms a recent growing trend of serious health conditions related to obesity that are becoming more prevalent in a younger demographic than ever before.

It highlighted nearly a third of children aged two to 15 years old were overweight or obese.

Chief executive Chris Askew said the figures were a worrying wake-up call.

NHS Digital data shows that people who get diabetes under 40 years old are more likely to:

Symptoms of diabetes can go completely missed because people think they are caused by something else.

Or their symptoms dont necessarily make them feel unwell, so they are not even acknowledged.

The most common early signs of type 2 diabetes are frequent urination, extreme thirst, and persistent hunger.

You should visit your GP if you are:

There are other symptoms that may alert you to this disease.

These include:

In children

Dan Howarth, Head of Care at Diabetes UK, said: The symptoms of diabetes needing the toilet more often than usual, feeling more tired or thirsty than normal, and unexplained weight loss are the same for people of all ages, and with all types of diabetes.

"Symptoms of type 1 diabetes develop very quickly, whereas type 2 diabetes symptoms come on more slowly.

"In children and young people with type 2 diabetes, symptoms may be less noticeable, with cases often going undetected."

But more specific problems to look out for are:

If your child is very overweight, the NHS says there are things you can to help them get to a healthy weight.

This includes upping exercise, keeping portions to child-sized, and eating healthier foods.

Exercise doesnt need to be any more than playing it, riding a bike, swimming or using a playground, so long as they are happy and moving.

All children need about 60 minutes of physical activity a day for good health, but it doesn't need to be all at once, the NHS says.

Food wise, children should avoid eating too much of the same things that cause weight gain in adults - sweets, chocolate, crisps and cakes.

Its important that as a parent, you also act as a good role model and try and get the whole family involved, so it doesnt feel like your child is targeted.

It can be a scary time if your child is diagnosed with diabetes, but doctors will be there to support you.

Your child will get a treatment plan that you as a parent will be involved with administering - including insulin injections.

You will also have to keep a close eye on your child's glucose levels to make sure they dont become dangerously low or high.

On top of this, children with diabetes will need to eat a healthy diet and exercise is considered incredibly important, Diabetes UK says.

Dan, Head of Care, said: Some people with type 2 diabetes can put their diabetes into remission through a combination of weight loss and lifestyle changes.

"While research into remission and young people with type 2 is ongoing, we know that by making lifestyle changes such as keeping physically active and eating healthily, families and young people with type 2 diabetes can increase their chances of remission, reduce their risk of diabetes-related complications risk and improve their overall health.

For more information about diabetes, visit diabetes.org.uk

Continue reading here:
Diabetes cases soar by 60% in just five years in under 25s know the signs... - The Sun

Many of the most groundbreaking discoveries have happened accidentally: The microwave oven, for one, was developed after physicist Percy Spencer noticed a chocolate bar in his pocket had melted while he was experimenting with a magnetron. Penicillin was born out of the bacteria-killing mold that grew on a petri dish while biologist Alexander Fleming was on vacation.

Perhaps aiming to join their ranks is Israeli startup Hagar, with itsGWave technology that measures blood sugar levels using noninvasive radio waves rather than an implanted sensor or repeated fingersticks.

According to Hagar lore, the technology came about after Geri Waintraub, the companys co-founder and chief technology officer, accidentally spilled a cup of tea on a radio frequency device during a separate research project and concluded that the ensuing reaction was caused by the sugar in his tea. Thus, GWave was born.

RELATED: Dexcom gets FDA go-ahead to pair diabetes data with Garmin, Livongo and more through 3rd-party APIs

The first generation of the GWave sensor is a device about a third the size of a standard smartphone,inserted into a ceramic bracelet. It uses Bluetooth to transmit its glucose readings to an accompanyingmobile app that tracks readings and alerts users to fluctuations in their blood sugar levels.

While radio waves are a form of electromagnetic radiation,GWave produces significantly less amounts than a smartphone, according to Hagar.

A proof-of-concept study found the company's radio frequency technology was able to continuously measure glucose levels with at least 90% accuracy, compared to the estimated 70% rate for traditional continuous glucose monitors.

According to the company, that difference stems from the fact that Hagars system directly measures glucose in the blood in real time. Other CGMs may use a sensor implanted under the skin to take measurements from the interstitial fluid between cells and may often have to be calibrated throughout the day with routine fingerstick blood tests.

RELATED: One Drop poaches Sanofi's head of diabetes innovation to bring CGM biosensor to market

Backed by those promising results, and with Hagar now planning to launch clinical trials to pursue FDA approval of the GWave system, the company has raised $11.7 million in series B funding.

The financing was led by Columbia Pacific and comes shortly after Hagar closed its series A, which brought in$4.4 million just last March. Those back-to-back funding rounds bring the companys lifetime funding to just over $17 million.

With 8.3% of the U.S. population living with diabetes today, that number is projected to rise to one in three adults by 2050. Finding a way to monitor glucose levels in the bloodcontinuously, painlessly and easilyis life-changing for those living with diabetes, and we are thrilled that our partners at Columbia Pacific are helping us in this journey, said CEO Guy Zur.

Next up, along with plotting out clinical trials of its technology, Hagar will continue developing the second-generation GWave device. In that iteration, the sensor will be embedded into a smartwatch that will be able to display the readings collected by the GWave mobile app.

Read the original:
Diabetes startup brews up $11M after 'serendipitous spill' led to creation of new CGM tech - FierceBiotech

GBS Inc. is presenting at the Benzinga Healthcare Small Cap Conference on September 29, 2021.

For some people with diabetes, testing with a pinprick is no more than a minor inconvenience. But for many adults with testing phobias, they not only face the possibility of a rapid heartbeat or even passing out but could also skip much-needed glucose testing, putting their lives at risk.

GBS Inc. (NASDAQ: GBS) understands that testing anxiety can be a life-or-death dilemma and is on a mission to develop non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at the point-of-care.

Point of care testing company, GBS, has developed the first saliva-based Biosensor Platform and is launching diagnostic tests to help change the lives of people with diabetes and help combat COVID-19 and its variants with a real-time antibody test to monitor infection and immunity levels.

The Companys most advanced product is the Saliva Glucose Biosensor. It uses an organic thin-film transistor, incorporating glucose oxidase as the recognition element to initiate an electrochemical reaction, producing a signal that displays glucose measurements in real-time on an app or dedicated device.

Diabetes is a global chronic health issue with more than 400 million people in the world living with this disease, and that figure is expected to increase to 700 million by 2045, GBS Chief Executive Officer Harry Simeonidis stated. People living with diabetes need to feel confident and comfortable using a glucose monitoring device to help manage and supplement their medication administration.

GBS has also conducted its own global survey of diabetes patients to verify the need for its Saliva Glucose Biosensor. In all target markets, 90% of patients responded positively to the Biosensor Platform, with 7 out of 10 patients seriously interested in purchasing the product when released, and 3 out of 10 wanting placement on the waiting list ahead of release.An interesting sidelight to the survey found that while patients in the United States indicated the price of a pain-free alternative to current glucose monitoring would play a role in determining their decision to upgrade to a new device, patients in China indicated price was not an issue, as long as the product was accurate and reliable. The global survey included more than 300 patients worldwide living with diabetes.

Story continues

COVID-19 Developments

Intending to gain U.S. Food and Drug Administration review, GBS has begun research protocols with The Wyss Institute for Biologically Inspired Engineering at Harvard University to progress with the milestone of integrating its technology with the Companys Biosensor for SARS-Cov-2 antibody tests.

GBS has also initiated a study for the salivary collection protocol with Johns Hopkins University, Bloomberg School of Public Health and has completed technical optimization of Wysss eRapid assay performance in relation to SARS-Cov-2 antibody detection at the institute to align with the fastest antibody tests currently on the market using clinical samples.

Australian Government Awards Grant

GBS has been awarded a $4.7 million (USD) grant from the Australian federal government. The funding will be used to build a biosensor manufacturing facility and was chosen as 1 of 6 national manufacturing priorities identified by the government under its Modern Manufacturing Strategy.

The Australian interest ties back to the roots of GBSs technology, which results from 20 years of research and development by the countrys University of Newcastle Centre for Organic Electronics.

For more information on GBS Inc., go to http://www.gbs.inc.

Photo courtesy of GBS Inc.

See more from Benzinga

2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read more here:
Life Sciences Company GBS Develops Technology to Take the Fear out of Diabetes and COVID Testing - Yahoo Finance